Aktienanalyse zu Compass Therapeutics Inc. (CMPX)CMPXCompass Therapeutics Inc.

Compass Therapeutics, Inc. is a clinical-stage, oncology-focused biopharmaceutical company. The Company is developing proprietary antibody-based therapeutics to treat multiple human diseases. Its pipeline of novel product candidates is designed to target multiple critical biological pathways required for an effective anti-tumor response. Its lead product candidate, tovecimig, is a bispecific antibody targeting Delta-like ligand 4 (DLL4), a ligand of Notch-1, and vascular endothelial growth factor A (VEGF-A). Its second program, CTX-471, is an agonistic antibody targeting a member of the tumor necrosis factor receptor superfamily member 9 (TNFRSF9), also known as CD-137, a co-stimulatory receptor which is mostly expressed on activated, but not on resting T-cells and NK cells. Its third program, CTX-8371, is a bispecific antibody targeting the programmed cell death protein-1 (PD-1), an inhibitory immune checkpoint receptor, and its ligand PD-L1, two validated immune-oncology targets. It operates in the Healthcare sector (BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES) industry).

Compass Therapeutics Inc. is a good buy right now due to its current price of $2.40, which is significantly lower than the analyst price target of $7, indicating a potential upside of over 200%. Additionally, the company has a strong cash position of $195 million, providing a runway until 2028, which supports its operational stability despite ongoing losses. However, the main risk is its negative earnings per share (EPS) of -0.13 reported in the latest quarter, indicating continued financial challenges.